ArticleFood science & nutrition2025
Luteolin Inhibits Dexamethasone-Induced Osteoporosis by Autophagy Activation Through miR-125b-5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Research Progress and Prospects of Flavonoids in the Treatment of Diseases by Regulating Autophagy: A Narrative Review.Molecules (Basel, Switzerland) · 2026Review
- Morinda officinalis polysaccharide improves osteoporosis by enhancing m⁶A-modified SOCS5 mRNA stability via regulating the hsa_circ_0001165/IGF2BP2 axis.Molecular genetics and genomics : MGG · 2026Article
- Mechanistic Modulation of Autophagy by Bioactive Natural Products: Implications for Human Aging and Longevity.Nutrients · 2026Review
- Protective Role of Luteolin against Endothelial Ferroptosis: Linking Antioxidant Pathways To Vascular Health.Cell biochemistry and biophysics · 2026Article
- The Role of Senolytics in Osteoporosis.Biomolecules · 2025Review
- Dexmedetomidine preserves neuronal function by promoting mitochondrial biogenesis through the AMPK/PGC-1α pathway.In vitro cellular & developmental biology. Animal · 2025Article
- Luteolin's Potential in Managing Osteoporosis and Bone Metabolism Disorders: Preclinical Insights.Drug design, development and therapy · 2025Review
- Luteolin reduces necroptosis in the diabetic heart after cardiac arrest and resuscitation by activating sirtuin 3.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin (LUT) has been suggested as an inhibitor of osteoporosis (OP). This investigation examines the pivotal role of the miR-125b-5p/SIRT3/AMPK/mTOR pathway in mediating luteolin-induced effects on OP. Mesenchymal stem cells derived from bone marrow (BMSCs) were exposed to dexamethasone (DEX) to create an in vitro model of OP. Following treatment with luteolin, the levels of miR-125b-5p and SIRT3 were quantified using reverse transcription polymerase chain reaction. Moreover, SIRT3, AMPK, mTOR protein levels, and osteogenesis (OPN, Runx2, OSX, and OCN), and autophagy (p62, ATG5, LC3, and BECN1) were evaluated using ELISA. Additionally, specific mimics and siRNA were constructed to overexpress miR-125b-5p or downregulate SIRT3. Furthermore, animal models of DEX-induced OP were constructed to assess the effects of LUT at doses of 50 and 100 mg/kg/day on bone histology, stereology, biochemistry, and the expression of the miR-125b-5p, SIRT3/AMPK/mTOR axis, and markers of osteogenesis and autophagy. The findings revealed that LUT suppressed miR-125b-5p expression, overexpressed SIRT3 and AMPK, and downregulated mTOR in BMSCs compared to DEX (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.